Eric Fowler, MD
Family Medicine · Reedsville, PANPI 1740217611
Payments from drug & device makers
Across 378 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$929
- GSK$718
- Novo Nordisk$619
- Lilly USA, LLC$479
- AbbVie$338
- AstraZeneca$281
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,530100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 78 | $929 |
| GSK | 62 | $718 |
| Novo Nordisk | 39 | $619 |
| Lilly USA, LLC | 24 | $479 |
| AbbVie(2 entities) | 16 | $338 |
| AstraZeneca | 18 | $281 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $194 |
| Boehringer Ingelheim | 14 | $190 |
| Abbott | 11 | $187 |
| Novartis | 12 | $175 |
| Exact Sciences | 7 | $152 |
| E.r. Squibb & Sons, L.L.C. | 10 | $147 |
| Johnson & Johnson | 9 | $126 |
| Amgen | 6 | $97 |
| Eisai Inc. | 3 | $91 |
| CSL Behring | 5 | $82 |
| Merck | 5 | $82 |
| Daiichi Sankyo Inc. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $65 |
| Biohaven Pharmaceuticals, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 3 | $52 |
| Biogen | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Amarin Pharma, Inc. | 3 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Philips North America LLC | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $23 |
| Neurelis, Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$125
How this compares
$5,552 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 340 | $319,938 |
| OzempicSemaglutide | 92 | $112,842 |
| JardianceEmpagliflozin | 108 | $87,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $79,332 |
| XareltoRivaroxaban | 71 | $54,816 |
| MyrbetriqMirabegron | 66 | $43,912 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $34,014 |
| MounjaroTirzepatide | 32 | $32,076 |
| RybelsusSemaglutide | 27 | $30,936 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $20,474 |
| TrulicityDulaglutide | 11 | $20,060 |
| TradjentaLinagliptin | 26 | $19,522 |
| ProliaDenosumab | 11 | $18,532 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $16,830 |
| FarxigaDapagliflozin Propanediol | 11 | $16,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $929 | $319,938340 claims |
| Novo NordiskOzempic, Rybelsus | $619 | $143,778119 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $718 | $128,897179 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Glyxambi | $190 | $121,579156 claims |
| Johnson & JohnsonXarelto | $126 | $54,81671 claims |
| Lilly USA, LLCMounjaro, Trulicity | $479 | $52,13643 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $43,91266 claims |
| AmgenProlia | $97 | $18,53211 claims |
| AstraZenecaFarxiga | $281 | $16,65611 claims |
| AbbVieLinzess | $338 | $7,96115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Reedsville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.